Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Gain Therapeutics (GANX) EPS (Basic) (2020 - 2025)

Historic EPS (Basic) for Gain Therapeutics (GANX) over the last 6 years, with Q3 2025 value amounting to -$0.15.

  • Gain Therapeutics' EPS (Basic) rose 1176.47% to -$0.15 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.61, marking a year-over-year increase of 4454.55%. This contributed to the annual value of -$1.0 for FY2024, which is 4140.72% up from last year.
  • According to the latest figures from Q3 2025, Gain Therapeutics' EPS (Basic) is -$0.15, which was up 1176.47% from -$0.19 recorded in Q2 2025.
  • Gain Therapeutics' EPS (Basic)'s 5-year high stood at -$0.15 during Q3 2025, with a 5-year trough of -$0.62 in Q2 2023.
  • For the 5-year period, Gain Therapeutics' EPS (Basic) averaged around -$0.33, with its median value being -$0.3 (2021).
  • As far as peak fluctuations go, Gain Therapeutics' EPS (Basic) crashed by 7241.38% in 2021, and later surged by 5476.19% in 2025.
  • Gain Therapeutics' EPS (Basic) (Quarter) stood at -$0.26 in 2021, then plummeted by 50.0% to -$0.39 in 2022, then grew by 25.64% to -$0.29 in 2023, then grew by 5.32% to -$0.27 in 2024, then soared by 45.37% to -$0.15 in 2025.
  • Its last three reported values are -$0.15 in Q3 2025, -$0.19 for Q2 2025, and -$0.16 during Q1 2025.